{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:37:13Z","timestamp":1761676633564,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:00:00Z","timestamp":1528934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81372611","81301750"],"award-info":[{"award-number":["81372611","81301750"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13048-018-0402-3","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T07:49:18Z","timestamp":1528962558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect"],"prefix":"10.1186","volume":"11","author":[{"given":"Duanyang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,14]]},"reference":[{"key":"402_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/1471-2407-14-288","volume":"14","author":"I Matte","year":"2014","unstructured":"Matte I, Lane D, Bachvarov D, Rancourt C, Pich\u00e9 A. Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer. 2014;14:288\u2013300.","journal-title":"BMC Cancer"},{"key":"402_CR2","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1001\/jama.291.22.2705","volume":"291","author":"BA Goff","year":"2004","unstructured":"Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291:2705\u201312.","journal-title":"JAMA"},{"key":"402_CR3","unstructured":"Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO classification of tumours of female reproductive organs. 4th ed. Lyon, editor: International Agency for Research on. Cancer. 2014:22\u20134."},{"key":"402_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/bjc.2012.343","volume":"107","author":"V Harding","year":"2012","unstructured":"Harding V, Fenu E, Medani H, et al. Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer. British Journal of Cancer. 2012;107:925\u201330.","journal-title":"British Journal of Cancer."},{"issue":"2","key":"402_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/cam4.196","volume":"3","author":"I Wada","year":"2014","unstructured":"Wada I, Matsushita H, Noji S, et al. Intraperitoneal injection of in vitro expanded Vc9Vd2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Medicine. 2014;3(2):362\u201375.","journal-title":"Cancer Medicine"},{"key":"402_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","volume":"104","author":"T Van Gorp","year":"2011","unstructured":"Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. British Journal of Cancer. 2011;104:863\u201370.","journal-title":"British Journal of Cancer"},{"issue":"12","key":"402_CR7","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1158\/1055-9965.EPI-11-0635","volume":"20","author":"E Bandiera","year":"2011","unstructured":"Bandiera E, Romani C, Specchia C, et al. Serum human epididymis protein 4 (HE4) and Risk for Ovarian Malignancy Algorithm (ROMA) as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011;20(12):2496\u2013506.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"402_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s13277-014-2738-7","volume":"36","author":"H Fujiwara","year":"2015","unstructured":"Fujiwara H, Suzuki M, Takeshima N, et al. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Tumor Biol. 2015;36:1045\u201353.","journal-title":"Tumor Biol."},{"key":"402_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1757-2215-7-22","volume":"7","author":"A Chudecka-G\u0142az","year":"2014","unstructured":"Chudecka-G\u0142az A, Cymbaluk-P\u0142oska A, Menkiszak J, Rzechu\u0142a AS, Byra E, Rzepka-G\u00f3rska I. HE4 tumor marker concentration in neoplastic peritoneal effusion and in peritoneal fluid associated with benign gynecological diseases. J Ovarian Res. 2014;7:22\u201331.","journal-title":"J Ovarian Res"},{"key":"402_CR10","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/jnci\/djr359","volume":"103","author":"N Urban","year":"2011","unstructured":"Urban N, Thorpe JD, Bergan LA, et al. Potential Role of HE4 in Multimodal Screening for Epithelial Ovarian Cancer. J Natl Cancer Inst. 2011;103:1630\u20134.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"402_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13048-015-0153-3","volume":"8","author":"GE B\u0119dkowska","year":"2015","unstructured":"B\u0119dkowska GE, \u0141awicki S, Gacuta E, Paw\u0142owski P, Szmitkowski M. M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients. Journal of Ovarian Research. 2015;8(1):27\u201338.","journal-title":"Journal of Ovarian Research."},{"key":"402_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1746-1596-8-11","volume":"8","author":"EO Hamed","year":"2013","unstructured":"Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagnostic Pathology. 2013;8:11\u20137.","journal-title":"Diagnostic Pathology"},{"key":"402_CR13","doi-asserted-by":"crossref","unstructured":"Alison Keen, Debbie Fitzgerald, Andrew Bryant and Heather O Dickinson. Management of drainage for malignant ascites in gynaecological Cancer. PMC 2014. CD007794. doi:10.1002\/14651858.CD007794.pub2.","DOI":"10.1002\/14651858.CD007794.pub2"},{"issue":"2","key":"402_CR14","first-page":"148","volume":"39","author":"ZHANG Yan","year":"2012","unstructured":"Yan ZHANG, Ya-li LI. Research Progress in Tumor Markers for the Early Diagnosis of Ovarian Cancer. [J] Int. Obstet Gynecol. 2012;39(2):148\u201351.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"402_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrclinonc.2010.44","volume":"7","author":"AK Karam","year":"2010","unstructured":"Karam AK, Karlan BY. Ovarian cancer: the duplicity of CA125 measurement [J]. Net Rev Clin Oncol. 2010;7(6):335\u20139.","journal-title":"Net Rev Clin Oncol"},{"issue":"11","key":"402_CR16","doi-asserted-by":"publisher","first-page":"618","DOI":"10.12659\/MSM.882046","volume":"17","author":"S-M He","year":"2011","unstructured":"He S-M, Xing F, Sui H, et al. Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer. Med Sci Monit. 2011;17(11):618\u201325.","journal-title":"Med Sci Monit"},{"issue":"4","key":"402_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1177\/1933719112459218","volume":"20","author":"JY Marina Frimer","year":"2012","unstructured":"Marina Frimer JY, Hou TC, McAndrew GL, Goldberg SS. The Clinical Relevance of Rising CA125 Levels Within the Normal Range in Patients With Uterine Papillary Serous Cancer. Reproductive Sciences. 2012;20(4):449\u201355.","journal-title":"Reproductive Sciences."},{"issue":"3","key":"402_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","volume":"68","author":"R Hassana","year":"2010","unstructured":"Hassana R, Schweizerb C, Kun F. Lua, et al. Inhibition of mesothelin-CA125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy. Lung Cancer. 2010;68(3):455\u20139.","journal-title":"Lung Cancer."},{"issue":"7","key":"402_CR19","doi-asserted-by":"publisher","first-page":"e0131579","DOI":"10.1371\/journal.pone.0131579","volume":"10","author":"L Mo","year":"2015","unstructured":"Mo L, Pospichalova V, Huang Z, Murphy SK, Payne S, Wang F, Kennedy M, Cianciolo GJ, Bryja V, Pizzo SV, Bachelder RE. Ascites Increases Expression\/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells. PLoS One. 2015;10(7):e0131579. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0131579\n                    \n                  . eCollection 2015.","journal-title":"PLoS One."},{"key":"402_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1095\/biolreprod45.2.350","volume":"45","author":"C Kirchhoff","year":"1991","unstructured":"Kirchhoff C, Habben I, Ivell R, Krull N. Amajor human epididymis specific cDNA encodesa protein with seqence homology toextra cellular protein naseinhibitors. Biol Repord. 1991;45:350\u20137.","journal-title":"Biol Repord"},{"key":"402_CR21","first-page":"1239","volume":"8","author":"X Liu","year":"2015","unstructured":"Liu X, Zhao F, Linli H, Sun Y. Value of detection of serum human epididymis secretory protein 4 and carbohydrate antigen 125 in diagnosis of early endometrial cancer of different pathological subtypes. OncoTargets and Therapy. 2015;8:1239\u201343.","journal-title":"OncoTargets and Therapy"},{"issue":"5","key":"402_CR22","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1245\/s10434-011-1943-5","volume":"19","author":"SY Kong","year":"2012","unstructured":"Kong SY, Han MH, Yoo HJ, et al. Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. Ann Surg Oncol. 2012;19(5):1707\u201312. \n                    https:\/\/doi.org\/10.1245\/s10434-%20011-1943-5\n                    \n                  . Epub 2011 Jul 21","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"402_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2012.11.023","volume":"128","author":"EI Braicu","year":"2013","unstructured":"Braicu EI, Fotopoulou C, Van Gorp T, et al. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol. 2013;128(2):245\u201351. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2012.11.023\n                    \n                  . Epub 2012 Nov 21.","journal-title":"Gynecol Oncol."},{"issue":"3","key":"402_CR24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1245\/s10434-013-3347-1","volume":"21","author":"EI Braicu","year":"2014","unstructured":"Braicu EI, Chekerov R, Richter R, et al. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse. Ann Surg Oncol. 2014;21(3):955\u201362. \n                    https:\/\/doi.org\/10.1245\/s10434-013-3347-1\n                    \n                  . Epub 2013 Nov 12","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"402_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1757-2215-5-20","volume":"5","author":"G Kalapotharakos","year":"2012","unstructured":"Kalapotharakos G, Asciutto C, Henic E, et al. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res. 2012;5(1):20. \n                    https:\/\/doi.org\/10.1186\/1757-2215-5-20\n                    \n                  .","journal-title":"J Ovarian Res."},{"issue":"12","key":"402_CR26","doi-asserted-by":"publisher","first-page":"12389","DOI":"10.1007\/s13277-014-2553-1","volume":"35","author":"T Vallius","year":"2014","unstructured":"Vallius T, Hynninen J, Auranen A, et al. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. Tumour Biol. 2014;35(12):12389\u201395. \n                    https:\/\/doi.org\/10.1007\/s13277-014-2553-1\n                    \n                  . Epub 2014 Sep 5","journal-title":"Tumour Biol."},{"key":"402_CR27","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.3390\/ijms16022956","volume":"16","author":"T Huang","year":"2015","unstructured":"Huang T, Jiang S-W, Qin L, Senkowski C, Lyle C, Terry K, Brower S, Chen H, Glasgow W. Yongchang Wei and Jinping Li .Expression and Diagnostic Value of HE4 in Pancreatic Adenocarcinoma. Int. J. Mol. Sci. 2015;16:2956\u201370.","journal-title":"Int. J. Mol. Sci."},{"key":"402_CR28","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/bjc.2011.109","volume":"104","author":"E Bignotti","year":"2011","unstructured":"Bignotti E, Ragnoli M, Zanotti L, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. British Journal of Cancer. 2011;104:1418\u201325.","journal-title":"British Journal of Cancer."},{"issue":"11","key":"402_CR29","doi-asserted-by":"publisher","first-page":"22655","DOI":"10.3390\/ijms141122655","volume":"14","author":"S-W Jiang","year":"2013","unstructured":"Jiang S-W, Chen H, Dowdy S, et al. HE4 Transcription- and Splice Variants-Specific Expression in Endometrial Cancer and Correlation with Patient Survival. Int. J. Mol. Sci. 2013;14(11):22655\u201377.","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"402_CR30","first-page":"548","volume":"27","author":"AR Simmons","year":"2013","unstructured":"Simmons AR, Baggerly K, Bast RC Jr. The Emerging Role of HE4 in the Evaluation of Advanced Epithelial Ovarian and Endometrial Carcinomas. Oncology (Williston Park). 2013;27(6):548\u201356.","journal-title":"Oncology (Williston Park)."},{"key":"402_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3892\/mco.2014.279","volume":"2","author":"S Zhen","year":"2014","unstructured":"Zhen S, Bian L-h, Chang L-l, Gao X. Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis. Molecular and Clinical Oncology. 2014;2:559\u201366.","journal-title":"Molecular and Clinical Oncology"},{"key":"402_CR32","doi-asserted-by":"crossref","unstructured":"Li F, Tie R, Chang K, et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: A meta-analysis. BMC Cancer. 2012(12):258\u201375.","DOI":"10.1186\/1471-2407-12-258"},{"key":"402_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/1471-2407-13-423","volume":"13","author":"D da Rocha Pitta","year":"2013","unstructured":"da Rocha Pitta D, Sarian LO, Barreta A, et al. CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses. BMC Cancer. 2013;13:423\u201333.","journal-title":"BMC Cancer"},{"issue":"1","key":"402_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1757-2215-6-45","volume":"6","author":"S \u0141awicki","year":"2013","unstructured":"\u0141awicki S, B\u0119dkowska GE, Gacuta-Szumarska E, Szmitkowski M. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. Journal of Ovarian Research. 2013;6(1):45\u201355.","journal-title":"Journal of Ovarian Research"},{"issue":"1","key":"402_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7314\/APJCP.2014.15.1.101","volume":"15","author":"WT Chen","year":"2014","unstructured":"Chen WT, Gao X, Han XD, et al. HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer. Asian Pac J Cancer Prev. 2014;15(1):101\u20135.","journal-title":"Asian Pac J Cancer Prev."},{"issue":"9","key":"402_CR36","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1097\/IGC.0b013e3182225509","volume":"21","author":"J Hynninen","year":"2011","unstructured":"Hynninen J, Auranen A, Dean K, et al. HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2011;21(9):1573\u20138. \n                    https:\/\/doi.org\/10.1097\/IGC.0b013e3182225509.","journal-title":"Int J Gynecol Cancer."},{"issue":"9","key":"402_CR37","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1097\/IGC.0b013e3182681cfd","volume":"22","author":"KD Steffensen","year":"2012","unstructured":"Steffensen KD, Waldstr\u00f8m M, Brandslund I, et al. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients. Int J Gynecol Cancer. 2012;22(9):1474\u201382. \n                    https:\/\/doi.org\/10.1097\/IGC.0b013e3182681cfd\n                    \n                  .","journal-title":"Int J Gynecol Cancer."},{"issue":"3","key":"402_CR38","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1007\/s13277-015-4031-9","volume":"37","author":"M Nassir","year":"2016","unstructured":"Nassir M, Guan J, Luketina H, et al. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study. Tumour Biol. 2016;37(3):3009\u201316. \n                    https:\/\/doi.org\/10.1007\/s13277-015-4031-9\n                    \n                  . Epub 2015 Sep 29","journal-title":"Tumour Biol."},{"issue":"2","key":"402_CR39","first-page":"830","volume":"5","author":"LC Zhu","year":"2015","unstructured":"Zhu LC, Gao J, Hu ZH, et al. Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. Am J Cancer Res. 2015;5(2):830\u201343.","journal-title":"Am J Cancer Res."},{"key":"402_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/srep03574","volume":"4","author":"M RG","year":"2014","unstructured":"RG M, EK H, T H, et al. HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. Sci Rep. 2014;4:3574. \n                    https:\/\/doi.org\/10.1038\/srep03574\n                    \n                  .","journal-title":"Sci Rep."},{"issue":"4","key":"402_CR41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41419-018-0449-5","volume":"9","author":"Y Liu","year":"2018","unstructured":"Liu Y, Tang J, Liu DY, Zhang L, He Y, Li J, Gao L, Tang D, Jin XM, Kong D. Increased autophagy in EOC re-ascites cells can inhibit cell death and promote drug resistance. Cell Death Dis. 2018;9(4):419. \n                    https:\/\/doi.org\/10.1038\/s41419-018-0449-5\n                    \n                  .","journal-title":"Cell Death Dis."}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-018-0402-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-018-0402-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-018-0402-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T19:13:56Z","timestamp":1560453236000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-018-0402-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,14]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1186\/s13048-018-0402-3","relation":{},"ISSN":["1757-2215"],"issn-type":[{"type":"electronic","value":"1757-2215"}],"subject":[],"published":{"date-parts":[[2018,6,14]]},"assertion":[{"value":"25 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional ethics committee of Harbin Medical University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors consent to the publication of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"47"}}